Riskpilot← Back to searchSign inGet full accessCALLUNA PHARMA AS
ASActiveOrg 932255189Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 202310 employees
Revenue 2024
NOK 26,9M
EBITDA margin
-99.0%
Equity ratio
90.1%
Financial strength
Net profit 2024
NOK -11,9M
10 employees
| Revenue | NOK 26,9M | — |
| EBITDA | NOK -26,6M | — |
| Net profit | NOK -11,9M | — |
| Total assets | NOK 853,6M | — |
| Equity | NOK 769,3M | — |
| Employees | 10 | — |
Legal name
CALLUNA PHARMA AS
Org number
932255189
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. oktober 2023
Share capital
NOK 1 041 669
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Å investere i farmasøytiske selskaper og virksomheter, herunder å realisere slike investeringer, samt all annen virksomhet knyttet til dette.
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 26 905 |
| Staff expenses | −32 017 |
| EBITDA | −26 638 |
| Depreciation & amort. | −0 |
| EBIT | −26 638 |
| Net financials | 14 727 |
| Profit before tax | −11 911 |
| Tax | −0 |
| Net profit | −11 911 |
| Item | 2024 |
|---|---|
| Total assets | 853 584 |
| Equity | 769 267 |
| Long-term debt | 0 |
| Short-term debt | 84 317 |
| Total debt | 84 317 |
EBITDA margin
-99.0%
This company
15.8%
Market median
-727% vs market
20242024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
20242024
Return on equity
-1.5%
This company
18.4%
Market median
-108% vs market
20242024
Net profit margin
-44.3%
This company
8.1%
Market median
-647% vs market
20242024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20242024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20242024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-09-01 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JG Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
MW Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Calluna Pharma Poolco As | Company | 47.2% | 47.2% | 2023 |
Forbion Capital Fund Iv Cooperatief | Company | 37.0% | 37.0% | 2023 |
Forcal I Investment Fund | Company | 11.2% | 11.2% | 2023 |
Stitching Administratiekantoor Oxit | Company | 4.7% | 4.7% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CALLUNA PHARMA AS 
ARXX THERAPEUTICS ASBoard members of CALLUNA PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Gary Montana | Chief Executive Officer | 0 companies |
| Mark William-Semrau Gaffney | Chief Executive Officer | 0 companies |
| Susanne Stuffers | Board of Directors | 0 companies |
| Johannes Jacob Pieter Kastelein | Board of Directors | 0 companies |
| Mark Frederick Altmeyer | Chairman | 0 companies |
| Farzad Abdi-Dezfuli | Board of Directors | 0 companies |
| Kristian Brekke Djuve | Chairman | 0 companies |
| Gijs Robert Van Den Brink | Board of Directors | 0 companies |
| Antoine Boulanger Piette | Board of Directors | 0 companies |
| Marco Boorsma | Chairman | 0 companies |